Aarti Industries Ltd · NSE:AARTIIND
Aarti Industries — Q2 FY20 Earnings Presentation
17 slides from Aarti Industries's earnings presentation, Nov 14, 2019
Slide 1: Cover letter to BSE and NSE
AARTI @l INDUSTRIES LIMITED Ref. No: AIL/B-39 l2OL9l612 November L4r 2OL9 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze .Jeej eebhoy Towers, India Limited Dalal Street, "Exchange Plaza" , Plot No. C I l, Mumbai - 400 001. G Block Ba
Slide 2: Q2 FY20 Results Presentation
AARTI INDUSTRIES LIMITED Q2 FY20 Results Presentation November 2019
Slide 3: Disclaimer
Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not
Slide 4: Agenda
Agenda 1 | At a glance 2 | Quarterly performance 3
Slide 5: Company Overview
Company Overview Overview Key Metrics A leading Speciality Chemicals company in Benzene based derivatives with integrated operations and high level of cost optimization Established by first generation technocrats in 1984 200+ 400+ 700+ Global Domestic Pharma operations spanning APIs, intermedi
Slide 6: Key Strengths
Key Strengths • Global Player in Benzene based Derivatives with Integrated Operations o Strong/Leadership position in key products and processes o Integrated operations across product chain of Benzene and Toluene o Ability to effectively use co-products and generate value-added products • Well Diver
Slide 7: Agenda
Agenda 1 | At a glance 2 | Quarterly performance 6
Slide 8: Chairman's Message
Chairman’s Message Commenting on the performance for Q2 FY20, Mr. Rajendra Gogri – Chairman & MD at Aarti Industries Ltd. said, “Our financial performance during Q2 is more representative of the planned transition that is happening in our core businesses. From the revenue standpoint, there are three
Slide 9: Q2 FY20 P&L (Standalone)
Q2 FY20 P&L (Standalone) Particulars Y-o-Y Y-o-Y (Rs. Crore) Q2 FY20 Q2 FY19 Growth Q1 FY20 H1 FY20 H1 FY19 Growth (%) (%) Adjusted for the demerger of Gross Income from Operations 1,019.0 1,299.5 -21.58% 1,086.1 2,105.1 2,378.0 -11.47% the HPC business, Q2 Exports 448.1 472.3 -5.1% 454.9 903.0 86
Slide 10: Q2 FY20 – Speciality Chemicals (Standalone)
Q2 FY20 – Speciality Chemicals (Standalone) Revenue Revenue 1888 Specialty Chemicals revenue lower due to decrease in raw material prices 1039 837 Lower RM price had impacted the 1732 revenue by 7%. Absolute EBIT maintained at almost stable levels despite weakness in some Q2 FY19 Q2 FY20 H1 FY
Slide 11: Q2 FY20 – Pharma (Standalone)
Q2 FY20 – Pharma (Standalone) Revenue Revenue 192 373 Pharma business revenue lower by 5% 342 YoY in Q2 and higher by 9% in H1. 182 Highest ever EBIT reported for the Pharma Segment Q2 FY19 Q2 FY20 H1 FY19 H2 FY20 Diversified contribution from domestic, regulated and non-regulated markets Fo
Slide 12: Revenue Performance (Consolidated)
Revenue Performance (Consolidated) Revenue Export Deep engagement with Operating revenues have grown on the back of global customers in CAGR: 13% 1,977 Speciality chemicals and strong volume growth in key business segments and 1,523 1,596 pharma. In addition, part 1,449 1,431 4,705 better product mi
Slide 13: EBIT Performance (Consolidated)
EBIT Performance (Consolidated) EBIT Higher growth relative to CAGR: 21% 932 revenue highlights value addition delivered by AIL 615 663 542 493 447 FY15 FY16 FY17 FY18 FY19 H1 FY20 Speciality Chemicals Pharmacuticals CAGR: 19% 819 CAGR: 33% 113 566 581 504 79 408 427 66 39 48 36 FY15 FY16 FY17 FY18
Slide 14: Balance-sheet as on 30.09.2019
Balance-sheet as on Standalone Consolidated Particulars 30.09.2019 31.03.2019 30.09.2019 31.03.2019 Property, Plant & Equipment 2,024 1,979 2,190 2,147 Capital Work-in-Progress 1,151 795 1,151 795 Investments 37 33 38 33 Inventories 753 701 805 772 Trade Receivables 914 806 879 776 Cash & Cash Equiv
Slide 15: Cash Flow (Consolidated)
Cash Flow (Consolidated) Particulars 30.09.2019 30.09.2018 31.03.2019 Net profit before Tax and Exceptional/ Extraordinary Items 361 284 622 Depreciations and Amortisation Expenses 89 82 163 (Increase)/ Decrease in Trade & Other Receivables -41 -72 -154 (Increase)/ Decrease in Trade Payable & Curren
Slide 16: Contact Us
Contact Us For further information please log on to www.aarti-industries.com or contact: Mr. Chetan Gandhi / Mr. Raj Sarraf Aarti Industries Limited Tel: +91 22 6797 6666 Email: info@aarti-industries.com Shiv Muttoo / Shruti Joshi CDR India Tel: +91 98335 57572 / +91 75065 67349 Email: shiv@cdr-indi
Slide 17: Thank You
| PRODUCTIVE [WITH SAF [Sear TL ART SA